Remifentanil

Generic Name: Remifentanil

Brand Names: Ultiva

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₈N_₂O_₅

CAS Number: 132875-61-7

Unique Ingredient Identifier: P10582JYYK

Background: Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia.

Indication: For use during the induction and maintenance of general anesthesia.

Associated Conditions: -

Associated Therapies: Immediate postoperative analgesia therapy, Induction and Maintenance of General Anesthesia, Monitored anesthesia care sedation

Clinical Trials

Comparison of Sufentanil, Fentanyl and Remifentanil in Combination With Midazolam During Bronchoscopy Under Conscious Sedation

Phase 4

Completed

Conditions: Remifentanil
Fentanyl
Sufentanil
Bronchoscopy
Narcotrend
Conscious Sedation

Interventions: Drug: Sufentanil
Drug: Fentanyl
Drug: Remifentanil
Drug: Midazolam

First Posted Date: 2019-04-03

Last Posted Date: 2019-04-03

Lead Sponsor: Guangzhou Institute of Respiratory Disease

Target Recruit Count: 60

Registration Number: NCT03901716

Locations: 🇨🇳
the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Sedation With Dexmedetomidine Versus Remifentanil in Urogynecological Surgery Under Spinal Anaesthesia

Phase 3

Conditions: Vaginal Hysterectomy
Suburethral Slings

Interventions: Drug: Dexmedetomidine
Drug: Remifentanil

First Posted Date: 2019-03-20

Last Posted Date: 2019-10-14

Lead Sponsor: University of Athens

Target Recruit Count: 50

Registration Number: NCT03883347

Locations: 🇬🇷
Aretaieio Hospital, University of Athens, Athens, Attiki, Greece

Sufentanil as Adjuvant of Balanced Anesthesia

Not Applicable

Completed

Conditions: Anesthesia

Interventions: Drug: Sufentanil
Drug: Remifentanil

First Posted Date: 2019-03-08

Last Posted Date: 2020-06-04

Lead Sponsor: Kangbuk Samsung Hospital

Target Recruit Count: 66

Registration Number: NCT03868111

Locations: 🇰🇷
Kangbuk Samsung Hospital, Seoul, Korea, Republic of

Hemodynamics During Induction of General Anesthesia After Prophylactic Ephedrine, Phenylephrine or Norepinephrine.

Phase 4

Completed

Conditions: Anesthesia, General
Anesthesia, Intravenous
Hemodynamic Instability

Interventions: Drug: Ephedrine
Drug: Phenylephrine
Drug: Norepinephrine
Drug: Sodium chloride
Drug: Propofol
Drug: Remifentanil

First Posted Date: 2019-03-06

Last Posted Date: 2024-10-04

Lead Sponsor: Helse Fonna

Target Recruit Count: 128

Registration Number: NCT03864094

Locations: 🇳🇴
Helse Fonna, Haugesund Sykehus, Haugesund, Norway

Investigation of the Strategy of Preventing Post-operative Opioid-induced Hyperalgesia

Phase 4

Conditions: Opioid-Induced Disorders

Interventions: Drug: Remifentanil

First Posted Date: 2019-01-22

Last Posted Date: 2019-01-22

Lead Sponsor: Tri-Service General Hospital

Target Recruit Count: 100

Registration Number: NCT03812003

Locations: 🇨🇳
Tri-Service General Hospital, Taipei, Taiwan

Does Precise Delivery of Remifentanil Decrease Coughing at Emergence From Anesthesia

Phase 4

Conditions: Cough

Interventions: Drug: Normal saline
Drug: Remifentanil

First Posted Date: 2018-12-21

Last Posted Date: 2018-12-24

Lead Sponsor: University of Vermont Medical Center

Target Recruit Count: 60

Registration Number: NCT03783676

MAC vs TIVA Ambulatory Breast Augmentation

Phase 3

Completed

Conditions: Breast Diseases

Interventions: Drug: general anesthetic
Drug: Remifentanil

First Posted Date: 2018-12-05

Last Posted Date: 2018-12-05

Lead Sponsor: Ain Shams University

Target Recruit Count: 80

Registration Number: NCT03764267

Comparison of Skin Sympathetic Nerve Activity According to Different Anesthetics

Not Applicable

Withdrawn

Conditions: SKNA According to Different Anesthetics

Interventions: Drug: Propofol continuous infusion
Drug: Sevoflurane
Drug: Desflurane
Drug: Propofol bolus injection
Drug: Remifentanil
Drug: Fentanyl

First Posted Date: 2018-12-04

Last Posted Date: 2022-05-11

Lead Sponsor: Seoul National University Hospital

Registration Number: NCT03763305

Effects of an Opioid Free/Sparing Care Pathway for Patients Undergoing Obesity Surgery

Not Applicable

Recruiting

Conditions: Pain, Postoperative
Obesity

Interventions: Drug: Remifentanil
Drug: Dexmedetomidine
Behavioral: Person-centred care (PCC)
Drug: Desflurane
Drug: Propofol
Drug: Esketamine
Drug: Oxycodone
Drug: Lidocaine
Device: Transcutaneous Nerve Stimulation (TENS)

First Posted Date: 2018-11-28

Last Posted Date: 2024-10-14

Lead Sponsor: Göteborg University

Target Recruit Count: 220

Registration Number: NCT03756961

Locations: 🇸🇪
Lindesberg Hospital, Lindesberg, Region Örebro, Sweden
🇸🇪
Sahlgrenska University hospital/ Östra hopsital, Gothenburg, VG, Sweden

Gradual Withdrawal of Remifentanil Infusion Reduced Postoperative Pain and Opioid Requirement During Breast Surgery

Not Applicable

Completed

Conditions: Pain, Postoperative

Interventions: Drug: Remifentanil

First Posted Date: 2018-11-28

Last Posted Date: 2019-09-11

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 60

Registration Number: NCT03756233

Locations: 🇰🇷
Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy